(0.29%) 5 114.62 points
(0.30%) 38 354 points
(0.31%) 15 978 points
(-0.95%) $83.05
(5.67%) $2.03
(0.37%) $2 356.00
(0.44%) $27.66
(3.99%) $958.85
(-0.21%) $0.933
(-0.37%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 5.41%
@ $136.99
発行日: 29 4月 2024 @ 22:30
リターン: 0.92%
前回のシグナル: 4月 26 - 23:27
前回のシグナル:
リターン: 0.71 %
Live Chart Being Loaded With Signals
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas...
Stats | |
---|---|
本日の出来高 | 193 829 |
平均出来高 | 887 675 |
時価総額 | 13.76B |
EPS | $0 ( 2024-02-07 ) |
次の収益日 | ( $1.040 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 55.75 |
ATR14 | $2.13 (1.54%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Benevich Eric | Buy | 12 587 | Common Stock |
2024-04-15 | Benevich Eric | Buy | 7 231 | Common Stock |
2024-04-15 | Benevich Eric | Sell | 12 587 | Common Stock |
2024-04-15 | Benevich Eric | Sell | 7 231 | Non-Qualified Stock Option |
2024-04-15 | Benevich Eric | Sell | 12 587 | Non-Qualified Stock Option |
INSIDER POWER |
---|
21.04 |
Last 100 transactions |
Buy: 793 011 | Sell: 504 436 |
ボリューム 相関
Neurocrine Biosciences 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Neurocrine Biosciences 相関 - 通貨/商品
Neurocrine Biosciences 財務諸表
Annual | 2023 |
収益: | $1.89B |
総利益: | $1.85B (97.90 %) |
EPS: | $2.56 |
FY | 2023 |
収益: | $1.89B |
総利益: | $1.85B (97.90 %) |
EPS: | $2.56 |
FY | 2022 |
収益: | $1.49B |
総利益: | $1.47B (98.44 %) |
EPS: | $1.610 |
FY | 2021 |
収益: | $1.13B |
総利益: | $1.12B (98.74 %) |
EPS: | $0.940 |
Financial Reports:
No articles found.
Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。